Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | AKT2 | P31751 | 2/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.44 |
| ▸ | MALT1 | Q9UDY8 | 2/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | PIM1 | P11309 | 1/20 | 0.43 |
| ▸ | KIT | P10721 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1350594 | 0.90 | AKT1 (0.50) | HSD11B1KMT2AMALT1HRH3PIM1 | |
| SCHEMBL1350596 | 0.90 | AKT1 (0.50) | HSD11B1KMT2AMALT1HRH3PIM1 | |
| SCHEMBL18239395 | 0.90 | AKT1 (0.50) | HSD11B1KMT2AMALT1HRH3PIM1 | |
| Hydrochloric Acid SCHEMBL18228382 | 0.89 | AKT1 (0.49) | HSD11B1KMT2AMALT1HRH3PIM1 | |
| SCHEMBL17206944 | 0.88 | HSD11B1 (0.50) | HSD11B1KMT2ATRPV1MALT1 | |
| SCHEMBL3552058 | 0.85 | KMT2A (0.61) | HSD11B1KMT2ATRPV1MALT1 | |
| SCHEMBL3436511 | 0.83 | SMO (0.53) | HSD11B1KMT2ATRPV1MALT1PIM1 | |
| SCHEMBL3436628 | 0.83 | HSD11B1 (0.49) | HSD11B1KMT2ATRPV1MALT1KDM4E | |
| SCHEMBL11962830 | 0.82 | HSD11B1 (0.45) | HSD11B1KMT2ATRPV1MALT1 | |
| SCHEMBL25888999 | 0.82 | HSD11B1 (0.45) | HSD11B1KMT2ATRPV1MALT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130296327-A1 | SUBSTITUTED HETEROCYLIC COMPOUNDS | INCYTE CORPORATION | 2013-11-07 | — | — | US | disclosed |
| US-8481732-B2 | Substituted heterocyclic compounds | INCYTE CORPORATION (US) | 2013-07-09 | — | — | US | disclosed |
| US-20100240671-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | INCYTE CORPORATION (US) | 2010-09-23 | — | — | US | disclosed |
| WO-2010108059-A1 | SUBSTITUTED PYRIMIDINE DERIVATIVES AS ANTAGONISTS OF THE HISTAMINE H4 RECEPTOR | INCYTE CORPORATION (US) | 2010-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130296327-A1 | SUBSTITUTED HETEROCYLIC COMPOUNDS | HRH4, HRH2, HRH1 | HSD11B1 2113/4885KMT2A 805/4885AKT2 3691/4885 |
| US-20100240671-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | HRH4, HRH2, HRH1 | HSD11B1 1868/4885KMT2A 1266/4885AKT2 3539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.